Chemoradiation plus immunotherapy for advanced cervical cancer
Part of Cancer, Immune system & allergy, Women’s health & pregnancy clinical trials.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have locally advanced cervical cancer that has not been treated before.
- You are in good enough health to undergo chemoradiation and immunotherapy.
- Your blood counts and liver/kidney function are within acceptable ranges.
- You do not have active autoimmune disease, hepatitis B or C, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests a new approach for advanced cervical cancer: giving immunotherapy (a drug that helps your immune system fight cancer) before and during standard chemoradiation. The goal is to see if adding immunotherapy can shrink the tumor more and improve outcomes.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Locally Advanced Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.